Re: Gilead GS-5829 Perspective

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gilead GS-5829 Perspective

in response to

Re: Gilead GS-5829 Perspective

Nextblockbuster

posted on Jul 24, 2017 10:51AM

Nbb - I have heard there are more than two companies at the table and something about mid to late September.